UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
Yanfang YangJing ZhaoYiran MaoGu LinFangxuan LiZhansheng JiangPublished in: Breast cancer research and treatment (2020)
These findings suggested that UBR5/β-catenin signaling might be a potential therapeutic target for TAM-resistant ERa+ breast cancer.